CASA > Inversores y Noticias > Anuncios

ISU Abxis Announced Korea Patent Protection for ‘ISU104’

  • 관리자
  • 2018-12-07
  • 319
ISU Abxis announced that Korean Intellectual Property Office (KIPO) has issued a new patent protecting the company’s novel drug candidate ‘ISU104’ for ‘the compositions and methods for preventing or treating resistant cancer’ on December 06, 2018.


‘ISU104’ is an antibody targeting ErBb3 that inhibits tumor growth and resistance to the current standard cancer treatments as blocking ligand-dependent ErbB3 activation and inhibiting dimerization of ErbB3 with ErbB1 or ErbB2 and now undergoing phase I trial focusing on targeting of ErbB3 for treatment of several types of solid tumors.
Ningún artículo anterior.
ISU Abxis Presents Phase 1 Data for ‘ISU304’ at WFH 2018 World Congress